PHVS Pharvaris Pharma: רווח נקי למניה ב-12 החודשים האחרונים

Pharvaris N.V. operates a business that is entirely independent of economic cycles due to the specific nature of rare disease therapies. The EPS YoY TTM growth value visualizes this resilience, where the current parameter equals 2.80. Asset value is driven by R&D progress rather than macroeconomics. The company is currently optimizing contract manufacturing capacities to scale the future production of its innovative oral medications.
PHVS (Pharvaris Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

An investor is assessing the margin of safety for Pharvaris N.V. (PHVS) by analyzing the growth rates of net income per share on a trailing twelve-month basis, which reveals the actual efficiency of the business capitalization. The implementation of robotic synthesis to combat orphan pathologies impacts operating expenses; therefore, the trend in the annual percentage change of EPS TTM determines the asset's status as a high-tech growth instrument.